{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1362825894166559744.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1002/cam4.106"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcam4.106"}},{"identifier":{"@type":"URI","@value":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.106"}},{"identifier":{"@type":"URI","@value":"https://onlinelibrary.wiley.com/doi/full-xml/10.1002/cam4.106"}}],"dc:title":[{"@value":"<scp>PD</scp>‐1 as a potential target in cancer therapy"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:title>Abstract</jats:title><jats:p>Recently, an improved understanding of the molecular mechanisms governing the host response to tumors has led to the identification of checkpoint signaling pathways involved in limiting the anticancer immune response. One of the most critical checkpoint pathways responsible for mediating tumor‐induced immune suppression is the programmed death‐1 (<jats:styled-content style=\"fixed-case\">PD</jats:styled-content>‐1) pathway, normally involved in promoting tolerance and preventing tissue damage in settings of chronic inflammation. Many human solid tumors express <jats:styled-content style=\"fixed-case\">PD</jats:styled-content> ligand 1 (<jats:styled-content style=\"fixed-case\">PD</jats:styled-content>‐L1), and this is often associated with a worse prognosis. Tumor‐infiltrating lymphocytes from patients with cancer typically express <jats:styled-content style=\"fixed-case\">PD</jats:styled-content>‐1 and have impaired antitumor functionality. Proof‐of‐concept has come from several preclinical studies in which blockade of <jats:styled-content style=\"fixed-case\">PD</jats:styled-content>‐1 or <jats:styled-content style=\"fixed-case\">PD</jats:styled-content>‐L1 enhanced T‐cell function and tumor cell lysis. Three monoclonal antibodies against <jats:styled-content style=\"fixed-case\">PD</jats:styled-content>‐1, and one against <jats:styled-content style=\"fixed-case\">PD</jats:styled-content>‐L1, have reported phase 1 data. All four agents have shown encouraging preliminary activity, and those that have been evaluated in larger patient populations appear to have encouraging safety profiles. Additional data are eagerly awaited. This review summarizes emerging clinical data and potential of <jats:styled-content style=\"fixed-case\">PD</jats:styled-content>‐1 pathway–targeted antibodies in development. If subsequent investigations confirm the initial results, it is conceivable that agents blocking the <jats:styled-content style=\"fixed-case\">PD</jats:styled-content>‐1/<jats:styled-content style=\"fixed-case\">PD</jats:styled-content>‐L1 pathway will prove valuable additions to the growing armamentarium of targeted immunotherapeutic agents.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1382825894166559744","@type":"Researcher","foaf:name":[{"@value":"David F. McDermott"}],"jpcoar:affiliationName":[{"@value":"Biologic Therapy Program Beth Israel Deaconess Medical Center Boston Massachusetts"},{"@value":"Harvard Medical School Boston Massachusetts"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825894166559745","@type":"Researcher","foaf:name":[{"@value":"Michael B. Atkins"}],"jpcoar:affiliationName":[{"@value":"Georgetown‐Lombardi Cancer Center Georgetown University School of Medicine Washington District of Columbia"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"20457634"},{"@type":"EISSN","@value":"20457634"}],"prism:publicationName":[{"@value":"Cancer Medicine"}],"dc:publisher":[{"@value":"Wiley"}],"prism:publicationDate":"2013-07-21","prism:volume":"2","prism:number":"5","prism:startingPage":"662","prism:endingPage":"673"},"reviewed":"false","dc:rights":["http://creativecommons.org/licenses/by/3.0/"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcam4.106"},{"@id":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.106"},{"@id":"https://onlinelibrary.wiley.com/doi/full-xml/10.1002/cam4.106"}],"createdAt":"2013-07-22","modifiedAt":"2023-10-06","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050856995324000512","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141"}]},{"@id":"https://cir.nii.ac.jp/crid/1360002219657848576","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004235487980288","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"<scp>PD</scp>‐1 expression on peripheral blood T‐cell subsets correlates with prognosis in non‐small cell lung cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360021391883224064","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Development of anti-feline PD-1 antibody and its functional analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285706389531648","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360286996864893440","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567182260859264","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Remarkable Short-Term Regression of a Posterior Mediastinum Metastasis From Primary Intraosseous Carcinoma Treated With Nivolumab: A Case Report"}]},{"@id":"https://cir.nii.ac.jp/crid/1360850167416642688","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Label-free classification of cells based on supervised machine learning of subcellular structures"}]},{"@id":"https://cir.nii.ac.jp/crid/1360857593778910464","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Gastrointestinal Adverse Events Induced by Immune-Checkpoint Inhibitors"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981470685926272","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1390024489446444032","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Ulcerative Colitis after Administration of Dupilumab, an Anti-interleukin-4 Receptor Subunit α Monoclonal Antibody: A Case Report"}]},{"@id":"https://cir.nii.ac.jp/crid/1390564237994063744","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Relapsed Myasthenia Gravis after Nivolumab Treatment"}]},{"@id":"https://cir.nii.ac.jp/crid/1390846609781414528","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Progression of Hypopituitarism and Hypothyroidism after Treatment with Pembrolizumab in a Patient with Adrenal Metastasis from Non-small-cell Lung Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1390853179619792384","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Colitis Induced by Immune-checkpoint Inhibitors"},{"@language":"ja","@value":"V．免疫チェックポイント阻害薬による大腸炎"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1002/cam4.106"},{"@type":"CROSSREF","@value":"10.1517/17425247.2014.955011_references_DOI_7s65yxoEX8Kar0ayqnGaZjN5KO5"},{"@type":"CROSSREF","@value":"10.1111/cas.12502_references_DOI_7s65yxoEX8Kar0ayqnGaZjN5KO5"},{"@type":"CROSSREF","@value":"10.3862/jcoloproctology.74.599_references_DOI_7s65yxoEX8Kar0ayqnGaZjN5KO5"},{"@type":"CROSSREF","@value":"10.1038/s41598-023-31543-6_references_DOI_7s65yxoEX8Kar0ayqnGaZjN5KO5"},{"@type":"CROSSREF","@value":"10.1007/s11060-018-2876-7_references_DOI_7s65yxoEX8Kar0ayqnGaZjN5KO5"},{"@type":"CROSSREF","@value":"10.1186/s12967-019-1957-5_references_DOI_7s65yxoEX8Kar0ayqnGaZjN5KO5"},{"@type":"CROSSREF","@value":"10.1159/000518543_references_DOI_7s65yxoEX8Kar0ayqnGaZjN5KO5"},{"@type":"CROSSREF","@value":"10.1016/j.oraloncology.2017.07.023_references_DOI_7s65yxoEX8Kar0ayqnGaZjN5KO5"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.5953-25_references_DOI_7s65yxoEX8Kar0ayqnGaZjN5KO5"},{"@type":"CROSSREF","@value":"10.1371/journal.pone.0211347_references_DOI_7s65yxoEX8Kar0ayqnGaZjN5KO5"},{"@type":"CROSSREF","@value":"10.1016/j.joms.2018.11.016_references_DOI_7s65yxoEX8Kar0ayqnGaZjN5KO5"},{"@type":"CROSSREF","@value":"10.1186/s12885-019-5380-3_references_DOI_7s65yxoEX8Kar0ayqnGaZjN5KO5"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.9153-17_references_DOI_7s65yxoEX8Kar0ayqnGaZjN5KO5"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.3008-19_references_DOI_7s65yxoEX8Kar0ayqnGaZjN5KO5"}]}